1. Home
  2. MTN vs RYTM Comparison

MTN vs RYTM Comparison

Compare MTN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vail Resorts Inc.

MTN

Vail Resorts Inc.

HOLD

Current Price

$150.93

Market Cap

5.2B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$108.41

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTN
RYTM
Founded
1997
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.8B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
MTN
RYTM
Price
$150.93
$108.41
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$162.58
$131.14
AVG Volume (30 Days)
719.4K
637.5K
Earning Date
06-04-2026
05-05-2026
Dividend Yield
7.27%
N/A
EPS Growth
24.05
28.34
EPS
9.43
N/A
Revenue
$2,964,347,000.00
N/A
Revenue This Year
N/A
$55.34
Revenue Next Year
$6.42
$86.06
P/E Ratio
$15.86
N/A
Revenue Growth
2.74
N/A
52 Week Low
$118.51
$74.50
52 Week High
$165.50
$122.20

Technical Indicators

Market Signals
Indicator
MTN
RYTM
Relative Strength Index (RSI) 55.33 55.70
Support Level $131.42 $98.76
Resistance Level $153.18 $113.03
Average True Range (ATR) 4.67 4.86
MACD -0.41 -0.41
Stochastic Oscillator 47.12 79.05

Price Performance

Historical Comparison
MTN
RYTM

About MTN Vail Resorts Inc.

Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: